(NASDAQ: MYGN) Myriad Genetics's forecast annual revenue growth rate of 6.89% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Myriad Genetics's revenue in 2026 is $806,600,000.On average, 11 Wall Street analysts forecast MYGN's revenue for 2026 to be $84,252,033,302, with the lowest MYGN revenue forecast at $80,538,914,083, and the highest MYGN revenue forecast at $87,426,645,019. On average, 11 Wall Street analysts forecast MYGN's revenue for 2027 to be $89,350,159,380, with the lowest MYGN revenue forecast at $83,819,696,906, and the highest MYGN revenue forecast at $94,727,582,422.
In 2028, MYGN is forecast to generate $94,169,944,992 in revenue, with the lowest revenue forecast at $87,219,085,290 and the highest revenue forecast at $102,536,419,440.